GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (STU:34D) » Definitions » Total Equity

Diasorin SpA (STU:34D) Total Equity : €1,615 Mil (As of Jun. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Diasorin SpA Total Equity?

Diasorin SpA's total equity for the quarter that ended in Jun. 2024 was €1,615 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Diasorin SpA Total Equity Historical Data

The historical data trend for Diasorin SpA's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diasorin SpA Total Equity Chart

Diasorin SpA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 848.62 956.32 1,367.94 1,519.75 1,537.97

Diasorin SpA Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,554.00 1,537.97 1,618.00 1,614.81 -

Diasorin SpA Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Diasorin SpA's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=3211.439-1673.471
=1,538

Diasorin SpA's Total Equity for the quarter that ended in Jun. 2024 is calculated as

Total Equity=Total Assets(Q: Jun. 2024 )-Total Liabilities(Q: Jun. 2024 )
=3125.513-1510.7
=1,615

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Total Equity Related Terms

Thank you for viewing the detailed overview of Diasorin SpA's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Diasorin SpA Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Diasorin SpA (STU:34D) » Definitions » Total Equity
Comparable Companies
TMO DHR XSWX:LONN A IDXX IQV SHSE:603259 MTD WAT NTRA LH DGX ICLR ILMN XPAR:BIM RVTY MEDP XPAR:ERF EXAS QGEN
Traded in Other Exchanges
DIA:Italy DIAm:UK 0GZX:UK 34D:Germany DIAS:Austria
Address
Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Website
https://www.diasoringroup.com
DiaSorin, headquartered in Italy, is a global provider of in vitro diagnostics, or IVD, which refers to testing done on samples taken from the human body, such as blood and tissue. DiaSorin produces and markets testing reagent kits for immunodiagnostics (about 65% of total sales) and molecular diagnostics (about 20%) and has a total installed base of about 9,000 diagnostic systems. Instruments and other revenue contribute about 15% of total sales. DiaSorin's largest market in 2023 was North America, which accounted for 48% of non-covid revenue, followed by Europe (35%) and the Rest of the World (18%).

Diasorin SpA Headlines

No Headlines